Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Significant Decrease in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a large decline in short interest in the month of October. As of October 30th, there was short interest totaling 2,140 shares, a decline of 88.8% from the October 15th total of 19,178 shares. Based on an average trading volume of 241,294 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Daiichi Sankyo Price Performance

Shares of OTCMKTS DSNKY opened at $17.68 on Wednesday. The firm has a market capitalization of $32.94 billion, a P/E ratio of 18.04, a P/E/G ratio of 2.08 and a beta of -0.10. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The stock’s 50-day simple moving average is $17.80 and its two-hundred day simple moving average is $17.57. Daiichi Sankyo has a twelve month low of $14.98 and a twelve month high of $24.77.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.08. The firm had revenue of $3.77 billion for the quarter, compared to analysts’ expectations of $3.58 billion. Daiichi Sankyo had a return on equity of 16.31% and a net margin of 12.13%. As a group, equities analysts anticipate that Daiichi Sankyo will post 0.87 EPS for the current fiscal year.

Analyst Ratings Changes

DSNKY has been the subject of a number of analyst reports. Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

About Daiichi Sankyo

Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).